| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68382-0244-16 | 68382-0244 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 42291-0352-30 | 42291-0352 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 11, 2016 | Sep 1, 2018 | No Longer Used |
| 42388-0024-37 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb 27, 2019 | In Use | |
| 00378-2246-93 | 00378-2246 | imatinib | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2017 | In Use | |
| 62332-0311-35 | 62332-0311 | Bosutinib | Bosutinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 00054-0248-12 | 00054-0248 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2018 | In Use | |
| 00173-0804-61 | 00173-0804 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | Oct 19, 2009 | Nov 30, 2017 | No Longer Used |
| 00093-7629-98 | 00093-7629 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 4, 2016 | In Use | |
| 70710-1745-03 | 70710-1745 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 59676-0030-84 | 59676-0030 | Erdafitinib | BALVERSA | 3.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Oral | Apr 12, 2019 | In Use | |
| 59651-0531-03 | 59651-0531 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
| 72205-0238-64 | 72205-0238 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 20, 2025 | In Use | |
| 42292-0053-05 | 42292-0053 | Erlotinib hydrochloride | Erlotinib Hydrochloride | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 28, 2019 | Jan 31, 2021 | No Longer Used |
| 50242-0064-01 | 50242-0064 | Erlotinib Hydrochloride | Tarceva | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2005 | In Use | |
| 54868-5427-03 | 54868-5427 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 9, 2005 | Jun 30, 2013 | No Longer Used | |
| 43598-0055-04 | 43598-0055 | Nilotinib | Nilotinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 63304-0116-13 | 63304-0116 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Oct 20, 2023 | In Use | |
| 43598-0345-30 | 43598-0345 | Imatinib | Imatinib | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 13, 2018 | In Use | |
| 76189-0535-60 | 76189-0535 | Ponatinib Hydrochloride | Iclusig | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 14, 2012 | Jul 26, 2020 | No Longer Used |
| 45629-0089-01 | 45629-0089 | Tivozanib | FOTIVDA | 0.89 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Mar 10, 2021 | In Use | |
| 65597-0407-20 | 65597-0407 | Pexidartinib hydrochloride | Turalio | 125.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Feb 1, 2023 | In Use | |
| 59923-0726-30 | 59923-0726 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 1, 2020 | In Use | |
| 46708-0311-35 | 46708-0311 | Bosutinib | Bosutinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 72064-0125-30 | 72064-0125 | avapritinib | Ayvakit | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Oral | Jun 16, 2021 | In Use | |
| 43598-0599-60 | 43598-0599 | Dasatinib | Dasatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use |
Found 12482 results — Export these results
Home